Advertisement

Cancer Immunology, Immunotherapy

, Volume 57, Issue 8, pp 1207–1214 | Cite as

Serum antibodies against Saccharomyces cerevisiae: a new prognostic indicator in metastatic renal-cell carcinoma

  • Reinhold Ramoner
  • Andrea Rahm
  • Hubert Gander
  • Björn Stollenwerk
  • Claudia Falkensammer
  • Nicolai Leonhartsberger
  • Martin ThurnherEmail author
Original Article

Abstract

Purpose

A recent study reported that a diet rich in bread and refined cereals might have an unfavorable role in the development of renal cell carcinoma (RCC). To test whether an underlying intolerance of bread ingredients is responsible for the unfavorable influence of bread on RCC, we examined patient sera for the presence of food-specific IgG.

Experimental design

A commercial test was used to detect food-specific IgG directed against a panel of 113 food antigens in sera of 54 patients with metastatic RCC. Kaplan–Meier estimates were used for univariate survival analysis, and differences in survival curves were assessed with the log-rank test. Multivariate survival analysis was done using a Cox regression model.

Results

We found that RCC patients with elevated serum levels of IgG antibodies against S. cerevisiae, commonly known as baker’s yeast and yet another bread component, have an unfavorable clinical course. Median survival of patients with high levels of S. cerevisiae IgG was only 17.8 months, whereas median survival of patients with low S. cerevisiae IgG was 43.8 months (P = 0.0022; log-rank). Multivariate survival analysis identified high levels of S. cerevisiae IgG as a strong and independent prognostic risk factor (risk ratio 4.6, P = 0.001; 95% CI 1.61–13.08).

Conclusions

Our findings indicate that serum levels of IgG against S. cerevisiae may predict survival in patients with metastatic RCC. The data suggest not cereals but baker’s yeast being the critical component of bread that may cause immune deviation and impaired immunosurveillance in predisposed RCC patients.

Keywords

Renal cell carcinoma Prognosis T helper cells 

Notes

Acknowledgments

We thank Christoph Eliskases for technical support. We also thank G. Bartsch, Head of the Department of Urology, for continuous support.

References

  1. 1.
    Acosta-Rodriguez EV, Napolitani G, Lanzavecchia A, Sallusto F (2007) Interleukins 1beta and 6 but not transforming growth factor-beta are essential for the differentiation of interleukin 17-producing human T helper cells. Nat Immunol 8:942–949PubMedCrossRefGoogle Scholar
  2. 2.
    Acosta-Rodriguez EV, Rivino L, Geginat J, Jarrossay D, Gattorno M, Lanzavecchia A, Sallusto F, Napolitani G (2007) Surface phenotype and antigenic specificity of human interleukin 17-producing T helper memory cells. Nat Immunol 8:639–646PubMedCrossRefGoogle Scholar
  3. 3.
    Annunziato F, Cosmi L, Santarlasci V, Maggi L, Liotta F, Mazzinghi B, Parente E, Fili L, Ferri S, Frosali F, Giudici F, Romagnani P, Parronchi P, Tonelli F, Maggi E, Romagnani S (2007) Phenotypic and functional features of human Th17 cells. J Exp Med 204:1849–1861PubMedCrossRefGoogle Scholar
  4. 4.
    Atkinson W, Sheldon TA, Shaath N, Whorwell PJ (2004) Food elimination based on IgG antibodies in irritable bowel syndrome: a randomised controlled trial. Gut 53:1459–1464PubMedCrossRefGoogle Scholar
  5. 5.
    Barta Z, Csipo I, Szabo GG, Szegedi G (2003) Seroreactivity against Saccharomyces cerevisiae in patients with Crohn’s disease and celiac disease. World J Gastroenterol 9:2308–2312PubMedGoogle Scholar
  6. 6.
    Berger S, Ballo H, Stutte HJ (1996) Immune complex-induced interleukin-6, interleukin-10 and prostaglandin secretion by human monocytes: a network of pro- and anti-inflammatory cytokines dependent on the antigen:antibody ratio. Eur J Immunol 26:1297–1301PubMedCrossRefGoogle Scholar
  7. 7.
    Berger S, Chandra R, Ballo H, Hildenbrand R, Stutte HJ (1997) Immune complexes are potent inhibitors of interleukin-12 secretion by human monocytes. Eur J Immunol 27:2994–3000PubMedCrossRefGoogle Scholar
  8. 8.
    Bossuyt X (2006) Serologic markers in inflammatory bowel disease. Clin Chem 52:171–181PubMedCrossRefGoogle Scholar
  9. 9.
    Bravi F, Bosetti C, Scotti L, Talamini R, Montella M, Ramazzotti V, Negri E, Franceschi S, La Vecchia C (2007) Food groups and renal cell carcinoma: a case–control study from Italy. Int J Cancer 120:681–685PubMedCrossRefGoogle Scholar
  10. 10.
    Brugarolas J (2007) Renal-cell carcinoma—molecular pathways and therapies. N Engl J Med 356:185–187PubMedCrossRefGoogle Scholar
  11. 11.
    Cohen HT, McGovern FJ (2005) Renal-cell carcinoma. N Engl J Med 353:2477–2490PubMedCrossRefGoogle Scholar
  12. 12.
    Dieterich W, Ehnis T, Bauer M, Donner P, Volta U, Riecken EO, Schuppan D (1997) Identification of tissue transglutaminase as the autoantigen of celiac disease. Nat Med 3:797–801PubMedCrossRefGoogle Scholar
  13. 13.
    Dunn GP, Koebel CM, Schreiber RD (2006) Interferons, immunity and cancer immunoediting. Nat Rev Immunol 6:836–848PubMedCrossRefGoogle Scholar
  14. 14.
    Fowler JE Jr (1986) Failure of immunotherapy for metastatic renal cell carcinoma. J Urol 135:22–25PubMedGoogle Scholar
  15. 15.
    Green PH, Jabri B (2006) Celiac disease. Annu Rev Med 57:207–221PubMedCrossRefGoogle Scholar
  16. 16.
    Gripp S, Moeller S, Bolke E, Schmitt G, Matuschek C, Asgari S, Asgharzadeh F, Roth S, Budach W, Franz M, Willers R (2007) Survival prediction in terminally ill cancer patients by clinical estimates, laboratory tests, and self-rated anxiety and depression. J Clin Oncol 25:3313–3320PubMedCrossRefGoogle Scholar
  17. 17.
    Holtl L, Ramoner R, Zelle-Rieser C, Gander H, Putz T, Papesh C, Nussbaumer W, Falkensammer C, Bartsch G, Thurnher M (2005) Allogeneic dendritic cell vaccination against metastatic renal cell carcinoma with or without cyclophosphamide. Cancer Immunol Immunother 54:663–670PubMedCrossRefGoogle Scholar
  18. 18.
    Holtl L, Zelle-Rieser C, Gander H, Papesh C, Ramoner R, Bartsch G, Rogatsch H, Barsoum AL, Coggin JH Jr, Thurnher M (2002) Immunotherapy of metastatic renal cell carcinoma with tumor lysate-pulsed autologous dendritic cells. Clin Cancer Res 8:3369–3376PubMedGoogle Scholar
  19. 19.
    Huang W, Na L, Fidel PL, Schwarzenberger P (2004) Requirement of interleukin-17A for systemic anti-Candida albicans host defense in mice. J Infect Dis 190:624–631PubMedCrossRefGoogle Scholar
  20. 20.
    Kay AB (2001) Allergy and allergic diseases. First of two parts. N Engl J Med 344:30–37PubMedCrossRefGoogle Scholar
  21. 21.
    Kleinrath T, Gassner C, Lackner P, Thurnher M, Ramoner R (2007) Interleukin-4 promoter polymorphisms: a genetic prognostic factor for survival in metastatic renal cell carcinoma. J Clin Oncol 25:845–851PubMedCrossRefGoogle Scholar
  22. 22.
    Langowski JL, Kastelein RA, Oft M (2007) Swords into plowshares: IL-23 repurposes tumor immune surveillance. Trends Immunol 28:207–212PubMedCrossRefGoogle Scholar
  23. 23.
    Langowski JL, Zhang X, Wu L, Mattson JD, Chen T, Smith K, Basham B, McClanahan T, Kastelein RA, Oft M (2006) IL-23 promotes tumour incidence and growth. Nature 442:461–465PubMedCrossRefGoogle Scholar
  24. 24.
    LeibundGut-Landmann S, Gross O, Robinson MJ, Osorio F, Slack EC, Tsoni SV, Schweighoffer E, Tybulewicz V, Brown GD, Ruland J, Reis e Sousa C (2007) Syk- and CARD9-dependent coupling of innate immunity to the induction of T helper cells that produce interleukin 17. Nat Immunol 8:630–638PubMedCrossRefGoogle Scholar
  25. 25.
    Lundin KE, Scott H, Hansen T, Paulsen G, Halstensen TS, Fausa O, Thorsby E, Sollid LM (1993) Gliadin-specific, HLA-DQ(alpha 1*0501,beta 1*0201) restricted T cells isolated from the small intestinal mucosa of celiac disease patients. J Exp Med 178:187–196PubMedCrossRefGoogle Scholar
  26. 26.
    Mejean A, Oudard S, Thiounn N (2003) Prognostic factors of renal cell carcinoma. J Urol 169:821–827PubMedCrossRefGoogle Scholar
  27. 27.
    Motzer RJ, Bacik J, Schwartz LH, Reuter V, Russo P, Marion S, Mazumdar M (2004) Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma. J Clin Oncol 22:454–463PubMedCrossRefGoogle Scholar
  28. 28.
    Motzer RJ, Bander NH, Nanus DM (1996) Renal-cell carcinoma. N Engl J Med 335:865–875PubMedCrossRefGoogle Scholar
  29. 29.
    Motzer RJ, Mazumdar M, Bacik J, Berg W, Amsterdam A, Ferrara J (1999) Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol 17:2530–2540PubMedGoogle Scholar
  30. 30.
    Muller S, Styner M, Seibold-Schmid B, Flogerzi B, Mahler M, Konrad A, Seibold F (2005) Anti-Saccharomyces cerevisiae antibody titers are stable over time in Crohn’s patients and are not inducible in murine models of colitis. World J Gastroenterol 11:6988–6994PubMedGoogle Scholar
  31. 31.
    Negrier S, Perol D, Menetrier-Caux C, Escudier B, Pallardy M, Ravaud A, Douillard JY, Chevreau C, Lasset C, Blay JY (2004) Interleukin-6, interleukin-10, and vascular endothelial growth factor in metastatic renal cell carcinoma: prognostic value of interleukin-6—from the Groupe Francais d’Immunotherapie. J Clin Oncol 22:2371–2378PubMedCrossRefGoogle Scholar
  32. 32.
    Neurath MF (2007) IL-23: a master regulator in Crohn disease. Nat Med 13:26–28PubMedCrossRefGoogle Scholar
  33. 33.
    Peeters M, Joossens S, Vermeire S, Vlietinck R, Bossuyt X, Rutgeerts P (2001) Diagnostic value of anti-Saccharomyces cerevisiae and antineutrophil cytoplasmic autoantibodies in inflammatory bowel disease. Am J Gastroenterol 96:730–734PubMedCrossRefGoogle Scholar
  34. 34.
    Quinton JF, Sendid B, Reumaux D, Duthilleul P, Cortot A, Grandbastien B, Charrier G, Targan SR, Colombel JF, Poulain D (1998) Anti-Saccharomyces cerevisiae mannan antibodies combined with antineutrophil cytoplasmic autoantibodies in inflammatory bowel disease: prevalence and diagnostic role. Gut 42:788–791PubMedCrossRefGoogle Scholar
  35. 35.
    Reiner SL (2007) Development in motion: helper T cells at work. Cell 129:33–36PubMedCrossRefGoogle Scholar
  36. 36.
    Shan L, Molberg O, Parrot I, Hausch F, Filiz F, Gray GM, Sollid LM, Khosla C (2002) Structural basis for gluten intolerance in celiac sprue. Science 297:2275–2279PubMedCrossRefGoogle Scholar
  37. 37.
    Sheibanie AF, Yen JH, Khayrullina T, Emig F, Zhang M, Tuma R, Ganea D (2007) The proinflammatory effect of prostaglandin E2 in experimental inflammatory bowel disease is mediated through the IL-23–>IL-17 axis. J Immunol 178:8138–8147PubMedGoogle Scholar
  38. 38.
    Sollid LM, Jabri B (2005) Is celiac disease an autoimmune disorder? Curr Opin Immunol 17:595–600PubMedCrossRefGoogle Scholar
  39. 39.
    Steinman L (2007) A brief history of T(H)17, the first major revision in the T(H)1/T(H)2 hypothesis of T cell-mediated tissue damage. Nat Med 13:139–145PubMedCrossRefGoogle Scholar
  40. 40.
    Wierecky J, Muller MR, Wirths S, Halder-Oehler E, Dorfel D, Schmidt SM, Hantschel M, Brugger W, Schroder S, Horger MS, Kanz L, Brossart P (2006) Immunologic and clinical responses after vaccinations with peptide-pulsed dendritic cells in metastatic renal cancer patients. Cancer Res 66:5910–5918PubMedCrossRefGoogle Scholar
  41. 41.
    Ye P, Rodriguez FH, Kanaly S, Stocking KL, Schurr J, Schwarzenberger P, Oliver P, Huang W, Zhang P, Zhang J, Shellito JE, Bagby GJ, Nelson S, Charrier K, Peschon JJ, Kolls JK (2001) Requirement of interleukin 17 receptor signaling for lung CXC chemokine and granulocyte colony-stimulating factor expression, neutrophil recruitment, and host defense. J Exp Med 194:519–527PubMedCrossRefGoogle Scholar
  42. 42.
    Zisman A, Pantuck AJ, Dorey F, Said JW, Shvarts O, Quintana D, Gitlitz BJ, deKernion JB, Figlin RA, Belldegrun AS (2001) Improved prognostication of renal cell carcinoma using an integrated staging system. J Clin Oncol 19:1649–1657PubMedGoogle Scholar

Copyright information

© Springer-Verlag 2008

Authors and Affiliations

  • Reinhold Ramoner
    • 1
  • Andrea Rahm
    • 1
  • Hubert Gander
    • 1
  • Björn Stollenwerk
    • 1
    • 2
  • Claudia Falkensammer
    • 1
  • Nicolai Leonhartsberger
    • 1
  • Martin Thurnher
    • 1
    Email author
  1. 1.Immunotherapy Unit, Department of UrologyInnsbruck Medical UniversityInnsbruckAustria
  2. 2.Department of Public Health, Medical Decision Making and Health Technology AssessmentUMIT—University for Health Sciences, Medical Informatics and TechnologyHall in TirolAustria

Personalised recommendations